The presence of a mutation in the MEK1 gene in melanoma patients does not cause resistance to BRAF inhibitor therapy in patients that also carry a BRAF mutation, according to a new study. Previously, experts believed that resistance to the drugs in BRAF-mutated melanoma patients could likely be blamed on the concurrent mutation in MEK1.
Scotland will soon begin a large prospective trial of early screening for lung cancer in high-risk patients using a simple blood test. The test, called EarlyCDT-Lung, has been in use and trials in the United States for more than two years.
Body mass index appears to be inversely associated with the risk for lung cancer, even after smoking status is carefully taken into account. A new prospective study found this association was restricted to current and former smokers and was actually stronger after adjustments for smoking were made.
Children diagnosed with non-central nervous system cancers at a very young age tend to reach some neurodevelopmental milestones later than healthy children, according to a new study.
Oral nutritional interventions can improve quality of life and overall nutritional intake in some cancer patients, but do not appear to have any effect on mortality outcomes, according to a recent meta-analysis.
ASCO Breast: Management of Breast Cancer in Young Patients Involves Complicated Surgical, Genetic, and Fertility Issues
In spite of screening recommendations that now begin only at 50 years of age, breast cancer is often diagnosed in women under the age of 40, and there are specific challenges to management of the disease in this younger population.
Triple-negative breast cancers represent a challenge for patients and clinicians, with poorer prognosis and fewer treatment options than other breast cancer subtypes. Recently, though, there have been suggestions that targeting pathways that repair DNA within tumor cells could provide benefit beyond the currently available treatments.
Treatments vary widely for metastatic breast cancer patients, though an analysis suggests that costs per patient are relatively similar across a number of different treatments.
A new study presented at the American Society of Clinical Oncology Breast Cancer Symposium in San Francisco shows that there is no survival difference between having a mastectomy or breast conservation therapy in women under the age of 40.